James Biehl - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.

Role
Chief Legal Officer
Signature
By: /s/ Richard Cunningham as attorney-in-fact for James Biehl
Issuer symbol
N/A
Transactions as of
16 Sep 2022
Net transactions value
$0
Form type
4
Filing time
16 Sep 2022, 18:00:35 UTC
Previous filing
26 Apr 2022
Next filing
02 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYME Common Stock Disposed to Issuer -105,000 -100% 0 16 Sep 2022 Direct F1
transaction TYME Common Stock Disposed to Issuer -150 -100% 0 16 Sep 2022 See Footnote F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -500,000 -100% 0 16 Sep 2022 Common Stock 500,000 $2.42 Direct F4
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -253,200 -100% 0 16 Sep 2022 Common Stock 253,200 $1.56 Direct F5
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -360,000 -100% 0 16 Sep 2022 Common Stock 360,000 $1.39 Direct F6
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -500,000 -100% 0 16 Sep 2022 Common Stock 500,000 $1.43 Direct F7
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -482,200 -100% 0 16 Sep 2022 Common Stock 482,200 $0.3200 Direct F8
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -12,500 -100% 0 16 Sep 2022 Common Stock 12,500 $2.95 Direct F9
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -12,500 -100% 0 16 Sep 2022 Common Stock 12,500 $2.95 Direct F10
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -75,000 -100% 0 16 Sep 2022 Common Stock 75,000 $2.90 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

James Biehl is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,601 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
F2 Disposed of pursuant to the merger agreement between the issuer and Syros in exchange for 6 shares of Syros common stock after giving effect to the Reverse Split, with cash paid in lieu of fractional shares.
F3 150 shares are owned by Mr. Biehl's spouse.
F4 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $55.23 per share, after giving effect to the Reverse Split.
F5 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 11,095 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.
F6 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 15,775 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.
F7 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
F8 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,130 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.
F9 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 547 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.
F10 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 547 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.
F11 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.